Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05457959
Title	Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Jonsson Comprehensive Cancer Center
Indications	diffuse glioma, H3 G34 mutant
Therapies	Nivolumab + Poly ICLC Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Poly ICLC DC tumor cell lysate vaccine + Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Nivolumab + Poly ICLC
Age Groups:	adult \| child
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
UCLA / Jonsson Comprehensive Cancer Center		Los Angeles	California	90095	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field